Testing Atezolizumab in People 2-17 Years Old With Clear Cell Sarcoma or Advanced Chondrosarcoma

Conditions

• Central Chondrosarcoma, Grade 2
• Central Chondrosarcoma, Grade 3
• Dedifferentiated Chondrosarcoma
• Metastatic Clear Cell Sarcoma of Soft Tissue
• Metastatic Primary Central Chondrosarcoma
• Unresectable Primary Central Chondrosarcoma

Eligibility Criteria

Sex

ALL

Age

2 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Atezolizumab — DRUG
  Given IV
• Biopsy Procedure — PROCEDURE
  Correlative studies
• Biospecimen Collection — PROCEDURE
  Correlative studies
• Computed Tomography — PROCEDURE
  Undergo CT scan

Study Details

This phase II trial studies how well atezolizumab works in treating patients with chondrosarcoma or clear cell sarcoma that is newly diagnosed, cannot be removed by surgery (unresectable), or has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.

Key Dates

Start date

Oct 5, 2020

Status verified

Dec 2025

Primary completion

Nov 28, 2022

Completion

Dec 17, 2026

Study Design

Enrollment

27 participants (actual)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Arms

• Experimental: Treatment (atezolizumab)
  Patients receive atezolizumab IV over 30-60 minutes on ay 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity. Patients undergo CT scans and undergo biopsy and collection of blood samples on study.

Primary Outcome Measure

Objective Response Rates (ORR) [ Time Frame: Baseline until confirmation of progressive disease or response (complete or partial) as defined by RECIST v1.1, an average of 4 months. ]

Locations (14)

Find similar trials in Los Angeles, CA